Profile cover photo
Profile photo
Dieter Lingelbach
3 followers
3 followers
About
Posts

Post has attachment
New vaccination candidate successful in Ad5 pre-immunization trial
Adenovirus overcomes another pressing challenge

Ad19a/64 has met yet another challenge in its validation process as novel vaccination candidate.

Adenovirus vectors enable the direct introduction of genetic antigen information into patients instead of inoculating them with inactivated pathogen. This method of direct antigen presentation is thought to hold the solution for a number of diseases currently unanswered by standard vaccination methods. Ad19a/64 has been considered highly promising in this context because it transduces human myoblasts and dendritic cells better than any other serotype.

One major disadvantage of adenoviral vectors for their clinical suitability is the existence of pre-acquired immunities to the common serotype Ad5 in humans. While this is not the case for novel Ad19a/64, until now it was uncertain if pre-acquired immunity against Ad5 may affect it as well.

Now, new results in mice, recently acquired by world renowned Prof. Peter Holst of the University of Copenhagen, show clearly that this serotype elicits comparable immune reactions against a given antigen as effective as Ad5, even in animals that were pre-immunized against the Ad5 serotype.

Add a comment...

Post has attachment
SIRION Biotech CEO discloses commercial collaborations potentially worth € 50 M to Europe's investment professionals in Frankfurt
Add a comment...

Post has attachment
new data - Achieve nearly 100% gene transfer into specialized cell types; Switching to customized adenovirus vectors - made easy

Specialized and primary cell types are difficult to treat with common lipid-based transfection methods. This limitation can be overcome; thanks to readily available adenoviral vectors (AV). Handling of the fully customizable AV particles is as easy as applying them to the cells; simply wash after 12-24 hrs.

Strong gene expression in patient-derived retinal pigment epithelial (RPE) cells after AV treatment.

RPE cells are a valuable target in ophthalmological research; they closely interact with photoreceptors to uphold visual function. Several forms of retinal degeneration can be traced to malfunction within this cell type. While RPE cells can be salvaged from tissue, the genetic modification is difficult – standard transfection methods reach only ~5% of all cells in a given population.

The figure  below demonstrates that adenovirus vectors by SIRION Biotech outperform standard methods and elicit a robust expression in nearly all cells even 6 weeks after transduction.
Add a comment...

Post has attachment
Access endothelial cells efficiently in vitro - new AAV gene tools
Long lasting expression, any gene or shRNA, inducible TET optional
Add a comment...

Post has attachment
Matured vector technologies open industrial gene therapy and vaccine markets to German Biotech, viral vectors gain traction in the industry
Add a comment...

Post has attachment
Breakthrough for preclinical vaccine vectors: New adenovirus serotype exceeds all expectations in first preclinical vaccination tests.

Munich, 21 December 2015 - Ad19a, the latest in adenoviral (AV) gene vector innovations, has generated first data in preclinical vaccination tests – with most promising results.
sirion-biotech.com

Virus technologies are a prime tool for targeted and highly controlled gene expression in mammalian cells and a hot candidate for modern vaccination R&D. Traditional vaccines are built from inactive or attenuated elements of a pathogen. Viral vectors on the other hand work as DNA or RNA transporters to reprogram a patient’s cells in order to produce a particular antigen and present it directly to
Organic
Add a comment...

Post has attachment
Launch of ProVector (TM) production cells upon significant interest expressed at Bio Europe last week. Industry experts add they provide protection from unwanted side effects during vector packaging by suppressing transgene expression. Call for ProVector when transgene expression during virus production interferes with the biology of standard packaging cells. Do not compromise scalability of your gene vector for in-vivo applications and accept an early end to otherwise promising vaccination strategies.
ProVector(TM) cells

		ProVector(TM) cells
sirion-biotech.com
Add a comment...

Post has attachment
Progress made with novel breakthrough vaccines: new production cell lines cope with difficult to express toxic antigens; 

Novelty at upcoming Bio Europe in Munich: SIRION Biotech announces high production yields for DNA based viral vectors with toxic antigens for vaccine production, see here: http://sirion-biotech.com/data/uploads/editor/files/151028%20Press%20Release%20novel%20vaccine%20production%20cell%20line_finale.pdf
Photo
Add a comment...

Post has attachment
Progress Published in Screening for New Cancer Compounds in Context of Radiation Therapy
Helmholtz’ Institute of Radiation Biology, SIRION Biotech and In-Sphero publish novel cell-based phenotypic assay 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460881/
Add a comment...

Post has attachment
SIRION Biotech Plans Opening of a New Office in the Boston Area http://bit.ly/1IkxEDD  @MassBio @MALifeSciences @sirionbiotechmu
Add a comment...
Wait while more posts are being loaded